In a novel application of dual-channel high-speed two-photon £uorescence microscopy, the skin auto£uores-cence and the transdermal £uorescent model drug spatial distributions were imaged simultaneously over precisely the same spatial coordinates. The dual channels enable the detection of the £uorescence emission wavelengths characteristic of the endogenous (intrinsic) skin £uorophores, as well as of the rhodamine-based model drug intensity emission at a di¡erent wavelength range of the £uorescence emission spectrum. These £uorescent model drugs delineate the oleic acid induced changes in permeant di¡usion with respect to the skin structural features over the 0.3 mm by 0.3 mm skin area imaged per skin sample. The dual-channel high-speed two-photon £uorescence microscopy studies presented here provide evidence for the existence of intracorneocyte di¡usion in addition to the commonly cited lipid multilamellar transdermal pathway. The image quanti¢cation analysis methodology introduced in this paper reveals that intracorneocyte di¡usion exists for the hydrophobic (rhodamine B hexyl ester) and for the hydrophilic (sulforhodamine B) model drugs, in the absence of oleic acid chemical enhancer action. The mechanism of oleic acid chemical enhancer action, however, depends on the model drug physicochemical properties, where the oleic acid induces hydrophobic model drug localization to the lipid multilamellar region, while increasing the hydrophilic model drug lipid to corneocyte partitioning. Key words: chemical enhancement mechanism/dual-channel high-speed two-photon £uorescence microscopy/oleic acid/skin auto£uorescence. J Invest Dermatol 120: 448^455, 2003 
In a novel application of dual-channel high-speed two-photon £uorescence microscopy, the skin auto£uores-cence and the transdermal £uorescent model drug spatial distributions were imaged simultaneously over precisely the same spatial coordinates. The dual channels enable the detection of the £uorescence emission wavelengths characteristic of the endogenous (intrinsic) skin £uorophores, as well as of the rhodamine-based model drug intensity emission at a di¡erent wavelength range of the £uorescence emission spectrum. These £uorescent model drugs delineate the oleic acid induced changes in permeant di¡usion with respect to the skin structural features over the 0.3 mm by 0.3 mm skin area imaged per skin sample. The dual-channel high-speed two-photon £uorescence microscopy studies presented here provide evidence for the existence of intracorneocyte di¡usion in addition to the commonly cited lipid multilamellar transdermal pathway. The image quanti¢cation analysis methodology introduced in this paper reveals that intracorneocyte di¡usion exists for the hydrophobic (rhodamine B hexyl ester) and for the hydrophilic (sulforhodamine B) model drugs, in the absence of oleic acid chemical enhancer action. The mechanism of oleic acid chemical enhancer action, however, depends on the model drug physicochemical properties, where the oleic acid induces hydrophobic model drug localization to the lipid multilamellar region, while increasing the hydrophilic model drug lipid to corneocyte partitioning. Key words: chemical enhancement mechanism/dual-channel high-speed two-photon £uorescence microscopy/oleic acid/skin auto£uorescence. J Invest Dermatol 120: 448^455, 2003 T he advantages of using two-photon £uorescence microscopy to examine a highly scattering and morphologically complex system, such as the skin have been described previously (Masters et al, 1997 (Masters et al, , 1998 Diaspro, 1999; Soeller and Cannell, 1999; Yu et al, 2001) , where some of the advantages include reduced sample photobleaching and increased three-dimensional depth discrimination. The evaluation of oleic acid-induced transdermal transport has focused in the past on the primary di¡usion pathway associated with the intercellular lipid region that was well delineated by both the hydrophobic and the hydrophilic model drugs (Gerritsen and de Grauw, 1999; Yu et al, 2002) . In this paper, we address the role of the corneocytes within the complex stratum corneum (SC) structure in the case of oleic acid-induced transdermal transport.
Until now, the study of chemical enhancer action has focused primarily on the alteration of the SC barrier properties resulting from a £uidization of the lipid multilamellar region through which the permeants di¡use (Golden et al, 1986 (Golden et al, , 1987 . The increased lipid disorder resulting from lipid £uidization has been cited as being responsible for the increase in drug partitioning into the SC, as well as for the increase in the porosity of the SC membrane (Yamashita et al, 1995; Yoneto et al, 1998) . Although chemical enhancer-induced deformation of the corneocytes has been described in studies using octyl glucoside (Lopez et al, 2000a, b) , the role of the corneocyte structures in transdermal transport processes has been largely neglected, primarily due to their relative impermeability when compared with that of the lipid multilamellar region (Matoltsy, 1976) .
As a new approach to identify the oleic acid-induced changes in intracorneocyte model drug penetration, a dual-channel highspeed two-photon £uorescence microscope (HTPM), used to ¢l-ter the £uorescence emission wavelengths in the green color spectrum range from the red color spectrum range, enables the simultaneous visualization of the £uorescence signals resulting from the intrinsic skin auto£uorescence in one channel and those signals resulting from the exogenous (or externally introduced) £uorescent model drug in the second channel. In current studies available in the literature (Grewal et al, 2000; Yu et al, 2001 Yu et al, , 2002 , the exogenous model drug £uorescence was examined without evaluating the corresponding skin auto£uorescence image. Hence, the £uorescent model drug spatial coordinates were evaluated without a visualization of the underlying SC structural features that govern the model drug di¡usion pathways. In this paper, we characterize the exogenous model drug spatial distributions in the skin with respect to the intrinsic skin auto£uores-cence at precisely the same skin spatial coordinates.
Skin auto£uorescence has been well studied in the literature, both in vivo and in vitro (Kollias et al, 1998; Gonzalez et al, 2000; Na et al, 2001 ). Using excitation wavelengths ranging from 340 nm to 380 nm, the skin auto£uorescence emission spectrum was detected using a £uorescence spectrophotometer that revealed two major component bands centered at 450 nm and 520 nm, that corresponded to 75% and 25% of the total spectrum intensity, respectively (Na et al, 2000) . These two peaks in the skin auto£uorescence spectrum correspond to the £uorescence emission peaks of the endogenous (or intrinsic) skin £uorophores, that include collagen, elastin, aromatic amino acids, such as tryptophan and tyrosine, nicotinamideadenine dinucleotide, porphyrins, and £avin adenine dinucleotide (Kollias et al, 1998) . The structural details of the corneocyte^lipid interface, delineated by imaging the intrinsic skin auto£uorescence, enables the quantitation of model drug spatial distributions relative to the corneocyte structures in the same skin sample, at precisely the same spatial locations.
MATERIALS AND METHODS
Skin sample preparation Using the methodology described previously (Yu et al, 2001 (Yu et al, , 2002 excised human cadaver skin (National Disease Research Interchange, Philadelphia, PA) was mounted in side-by-side di¡usion cells (Permegear, Riegelsville, PA). The model drug control and enhancer vehicle solutions consisted of 50/50 v/v phosphate-bu¡ered saline/ ethanol and of the control solution containing an additional 5% oleic acid (Sigma, St Louis, MO), respectively. The hydrophobic and the hydrophilic model drug concentrations of rhodamine B hexyl ester (RBHE) and sulforhodamine B (SRB) (Molecular Probes, Eugene, OR), respectively, were adjusted such that the exogenous £uorescent model drug intensity signal detected was comparable with the endogenous SC auto£uorescence intensity. The dilution of the RBHE and SRB vehicles to 0.005 mg per ml (compared with the 0.33 mg per ml utilized in the studies reported previously; Yu et al, 2001 Yu et al, , 2002 enables the simultaneous imaging of the skin auto£uorescence as well as of the exogenous £uorescent model drug intensities, such that model drug signal saturation is avoided. After 24 h of skin exposure to the model drug solution, the samples were rinsed with phosphate-bu¡ered saline, and mounted on microscope slides as described previously (Yu et al, 2002) .
HTPM A detailed description of the HTPM methodology utilized in these studies can be found in the literature (Kim et al, 1999) . Modi¢cations to the HTPM instrumentation include the use of a ¢lter set (Chroma Technologies, Brattleboro, VT) that separates the £uorescence emission signal into two wavelength ranges. The ¢lter set consists of a dichroic mirror (part no. 530DCXR), a short pass ¢lter (part no. E535SP), and a bandpass ¢lter (part no. D630/40). The dichroic mirror re£ects emission wavelengths below 530 nm to one channel, where the short pass ¢lter is applied. Fluorescence emission signals in the range of 610 nm to 650 nm, that are re£ected from the dichroic mirror, are detected in the second channel using the bandpass ¢lter. The ¢rst channel collects the emission wavelengths characteristic of the intrinsic skin £uorophores, and will be referred to as the green channel. The second channel, or the red channel, detects the model drug £uorescence signal (Table I lists the absorption and emission wavelengths of each model drug). The model drug spatial distributions in the following studies were evaluated in nine consecutive skin sites, each skin site having an area of 100 mm by 100 mm.
At the laser power used, the skin auto£uorescence intensities treated with the control and the enhancer vehicle solutions in the presence and in the absence of the model drugs are comparable. This comparison of the skin auto£uorescence intensities veri¢es that the skin auto£uorescence signal detected in the green channel arises from the endogenous skin £uorophores, and not from signal noise introduced by the model drugs.
Image analysis of model drug spatial distributions To elucidate the role of intracorneocyte di¡usion in transdermal transport, nine consecutive skin sites (600 Â 600 pixels in image size) representative of a continuous skin region containing well de¢ned, regularly spaced corneocytes, were selected for each skin sample. To focus on the SC structural dimensions de¢ned by the skin auto£uorescence and by the model drug intensity signals, a representative subregion, spanning 150 Â 150 pixels, was selected from the total 600 Â 600 pixels skin image acquired for each condition: RBHE-control, RBHE-enhancer, SRB-control, and SRB-enhancer. Within each 150 Â 150 pixel image, a linear path of 5 pixels in width (y coordinate) and 150 pixels in length (x coordinate) was deconstructed into its pixel intensity values to determine the intercellular region width, de¢ned by the £uorescence intensity peak widths. At each position along the x coordinate, the intensities of the corresponding 5 pixels were averaged. The arbitrarily selected line width of 5 pixels accounts for the intensity variations along the y coordinate while limiting the inclusion of intensities arising from di¡erent structural features in the average value. The resulting plot of the £uorescence intensity spectrum for the green channel, as a function of the x coordinate position, reveals the peak-topeak distance as well as the peak width, which indicate the corneocyte width and the intercellular spacing, respectively, along the 150 pixel linear region analyzed. The corresponding plot of the model drug £uorescence intensity spectrum for the red channel describes the model drug spatial distribution relative to the skin structural features de¢ned by the skin auto£uorescence intensity spectrum. These skin auto£uorescence and model drug intensity spectra are then normalized with respect to the corresponding maximum £uorescence intensities detected within the selected linear path. Because the skin auto£uorescence and the model drug £uorescence signals span two di¡erent intensity ranges, the £uorescence intensity normalization enables a comparison of the relative changes in the spatial intensity distributions between these two £uorescence intensity signals using the same normalized scale, where zero values re£ect the absence of a £uorescence intensity signal and values of 1 represent maximum £uorescence intensity signals.
RESULTS AND DISCUSSION
Visualization of £uorescent model drug spatial distributions The HTPM dual-channel imaging visualizations of the skin auto£uorescence and of the exogenous model drug intensity are presented in Figs 1 and 2 for the hydrophobic model drug RBHE and for the hydrophilic model drug SRB, respectively.
Hydrophobic model drug (RBHE)
The black regions that are surrounded by the green intercellular auto£uorescence depict the corneocyte structures for the control case (see Fig 1a) . Based on the length of the 100 mm scale bar provided at the lower left of Fig 1(a) , the corneocyte dimensions are approximately 30 mm, which is consistent with the 30^40 mm diameter reported in the literature (Heisig et al, 1996) .
A comparison of the skin auto£uorescence image for the control RBHE case (Fig 1a) with the RBHE-control model drug spatial distribution (Fig 1b) indicates that RBHE primarily traverses the intercellular region. In the overlay of the green and the red channels shown in Fig 1(c) , a majority of the RBHE signal is observed to be positioned within the intercellular space delineated by the skin auto£uorescence. In Fig 1(b) , the corneocyte structures exhibit a lower £uorescence intensity compared with the intercellular lipid multilamellar region model drug intensity, located at the perimeter of the corneocyte structures. This ¢nding is consistent with previous studies using HTPM aimed at elucidating the mechanisms of chemical enhancer action (Yu et al, 2002) . The visualization of RBHE model drug £uorescence within the periphery of the corneocyte structures, however, indicates that intracorneocyte di¡usion may result from the £uorescent model drug concentration di¡erence between the intercellular region and the £uorescent model drug de¢cient corneocyte interior.
The oleic acid-induced changes in the RBHE spatial distribution are observed upon comparing Fig 1(d,e) . The MW is the molecular weight of each probe; ab/em indicates the probe spectral absorption (ab) and emission peaks (em); logK O/PBS , re£ects the measured values of the log of the probe PBS-octanol partition coe⁄cients (Yu et al., 2001) .
b Values are reported as mean7SD. Experiments were performed in triplicate overlap of the green and the red channels, shown in Fig 1(f) , indicates con¢nement of the RBHE signal position to the intercellular region de¢ned by the skin auto£uorescence image (Fig 1d) . Furthermore, the oleic acid induced formation of the hydrophobic drug microdomains are observed at the upper and at the lower bright, white, regions of Fig 1(e) . Compared with the control case (Fig 1b) , these microdomains observed in the enhancer case contribute to increased heterogeneity in the model drug spatial distribution. A comparison of the skin auto£uorescence (Fig 1d) with the oleic acid-induced hydrophobic model drug spatial distribution (Fig 1e) indicates a decrease in the model drug intracorneocyte penetration with respect to the control case. Figure 2 (a) shows the SC auto£uorescence signal for the hydrophilic model drug (SRB) control case. The corneocytes are the dark polyhedral regions surrounded by the green auto£uorescence of the SC intercellular region. The similarity in skin auto£uorescence intensity distributions for the hydrophobic model drug (Fig 1a) and for the hydrophilic model drug (Fig 2a) control cases indicates that the intrinsic SC auto£uorescence is independent of model drug speci¢c penetration pathways. The £uorescent model drug spatial distributions can therefore be characterized relative to these maps of the intrinsic skin structural features. The SRB model drug spatial distribution shown in Fig 2(b) further highlights the intercellular di¡usion pathway speci¢c to the physicochemical properties of the hydrophilic £uorescent model drug. As observed in the wide-area visualization of hydrophilic model drug SRB distributions reported in a previous paper (Yu et al, 2002) , SRB lies primarily within the intercellular region. The overlapping of the £uorescence signals from the green and the red channels shown in Fig 2(c) further demonstrates that the SRB model drug spatial distribution is primarily located within the intercellular region de¢ned by the skin auto£uorescence. The appearance of SRB model drug intensity within the corneocyte region provides evidence for hydrophilic model drug penetration into the corneocyte region. As described earlier for the RBHE-control case, the SRB intracorneocyte di¡usion, visualized in Fig 2(b) , may be attributed to the model drug concentration di¡erence between the primary hydrophilic model drug transport pathway of the intercellular region and the model drug-de¢cient corneocyte regions.
Hydrophilic model drug (SRB)
In the presence of oleic acid chemical enhancer action, increased hydrophilic model drug intensities were visualized within the corneocyte region. Compared with the corresponding auto£uorescence signals, the oleic acid-induced SRB spatial distribution detected in the red channel (see Fig 2e) highlights a continuous phase that is broader than the one detected in the green channel (see Fig 2d) . Overlapping the signals detected in the red and the green channels indicates the extent of SRB intracorneocyte penetration (Fig 2f) , where the £uorescence signal detected through the red channel extends into the corneocyte regions outlined by the green channel.
A quanti¢cation of the observations made above is presented below.
Linear image deconstruction of intracorneocyte model drug intensity distributions For each skin sample, Figs 3 and 4 capture the linear deconstruction paths examined within the context of the surrounding 150 Â 150 pixel skin area. The £uorescence intensity spectra shown for the RBHE-control, the RBHE-enhancer, the SRB-control, and the SRB-enhancer cases in Figs 3(b) , 3(e), 4(b), and 4(e), respectively, represents the deconstruction of the £uorescence images along one dimension (see Materials and Methods above). Fig 3(b) , the model drug intensity spectrum (red line) envelopes the auto£uorescence spectrum (green line). The wider model drug intensity spectrum peaks, relative to the referenced peak widths of the corresponding auto£uorescence spectrum, indicate that the model drug transport extends beyond the intercellular region de¢ned by the skin auto£uorescence intensity spectrum and into the corneocyte structures. Compared with the zero intensity minima exhibited by the skin auto£uorescence spectrum, the model drug intensity spectrum minima never approach zero. The model drug intensities detected within the corneocyte regions further corroborate the existence of intracorneocyte model drug penetration potentially driven by the model drug concentration gradient from the intercellular region into the corneocyte region.
Hydrophobic model drug (RBHE) For the RBHE-control in
In the presence of oleic acid, however, RBHE becomes localized to within the de¢ned intercellular space. The intensity spectra shown in Fig 3(e) indicate that the widths of the auto£uorescence intensity peaks (located at x ¼ 60 pixels and at x ¼ 140 pixels) extend beyond the corresponding peak widths for the model drug intensity spectrum. In enhancing transdermal transport of the hydrophobic model drug, the action of the oleic acid chemical enhancer is observed in the localization of the RBHE distribution, ¢rst to the intercellular region, and second, to the larger domains of high model drug intensity (white regions at the top and at the bottom of Fig 1e) , referred to earlier as microdomains of model drug distribution.
Hydrophilic model drug (SRB) Figure 4(b) shows the SRB-control sample intensity spectrum (red line), corresponding to the white rectangle highlighted in Fig 4(a) , and the auto£uorescence spectrum (green line), corresponding to the white rectangle highlighted in Fig 4(c) . In Fig 4(b) , the SRB-control auto£uorescence spectrum (green line) exhibits two major peaks at x ¼ 21 pixels and at x ¼ 103 pixels, with minor peaks at x ¼ 56 pixels and at x ¼ 150 pixels. These four peaks correspond to the positions of the intercellular regions shown in the white rectangle demarking the linear path evaluated in the corresponding skin auto£uorescence image (Fig 4c) .
The SRB model drug intensity spectrum peak widths (see red line in Fig 4b) are greater than those corresponding to the skin auto£uorescence peaks (see green line in Fig 4b) at the four xcoordinates noted. This di¡erence between the model drug intensity and the skin auto£uorescence peak widths indicates that the model drug does penetrate into the corneocyte region, although not to the same extent as for the SRB-enhancer case (described below). The minima corresponding to the SRBcontrol intensity spectrum in Fig 4(b) (see red line at x ¼ 40 and 75 pixels) do reach the zero intensity value as the spatial position approaches the corneocyte center and away from the intercellular region. The additional peak detected only for the model drug intensity at x ¼ 120 pixels provides evidence of model drug penetration into the corneocyte region. The peakto-peak region of the auto£uorescence spectrum (see green line in Fig 4b) from x ¼ 103^150 pixels outlines the outer bounds of a corneocyte. The model drug intensity peak at x ¼ 120 pixels, as well as the nonzero model drug intensities detected within the corresponding corneocyte region (see red line in Fig 4b from x ¼ 103^150 pixels), indicate model drug penetration within this corneocyte region. Compared with the di¡erences between the hydrophobic model drug peak widths and their corresponding auto£uorescence peak widths, the hydrophilic model drug control case displays less intracorneocyte di¡usion.
The oleic acid-induced increase in the penetration of the hydrophilic model drug (SRB) into the corneocyte region is observed in the spectra shown in Fig 4(e) , in which the model drug peak widths far exceed the auto£uorescence peak widths that outline the boundary of the intercellular region. The oleic acid-induced increased partitioning of SRB into the SC intercellular region, which was quanti¢ed previously (Yu et al, 2001 (Yu et al, , 2002 , increases the model drug concentration in the intercellular region. The drop in model drug intensity (red line in Fig 4e) about the peak maximum re£ects the concentration gradient driving SRB di¡usion into the corneocytes. In contrast to its e¡ect on the hydrophobic model drug localization to the intercellular region, the increased concentration of SRB in the intercellular region contributes to the oleic acid-induced intracorneocyte penetration observed in Fig 4(d) , where the model drug intensity does not drop to zero in the corneocyte regions.
Based on the visual elucidation of transport pathways through the decomposition of the skin auto£uorescence signals from the model drug £uorescence signal, oleic acid was observed to increase intracorneocyte penetration for the hydrophilic model drug and to localize hydrophobic model drug di¡usion to either the intercellular region or to the larger domains (''pools'') of high model drug intensity.
Implications of the role of corneocyte di¡usion on transdermal transport The oleic acid-induced increase in SRB lipid to corneocyte partitioning is observed in the model drug di¡usion into the corneocytes. The availability of corneocyte di¡usion as a secondary pathway suggests that the constraints to transdermal transport via lateral di¡usion through the tortuous intercellular multilamellae no longer hold. Therefore, the oleic acid-induced increase in SRB model drug di¡usion into the corneocytes remains consistent with earlier ¢ndings that the hydrophilic model drug vehicle to SC partitioning is the rate-limiting step (Yu et al, 2002) . Furthermore, the hydrophobic model drug rate-limiting step of lateral di¡usion coincides with the oleic acid-induced localization of the hydrophobic model drug to domains within the intercellular region. This conclusion remains consistent with the transport hindrance presented by the tortuous lipid multilamellae region for the hydrophobic model drugs established earlier by Johnson et al (1997) , and more recently Yu et al (2002) .
For the hydrophobic model drug, the model drug localization to the intercellular region, as well as to discrete domains within the SC, could be attributed to the inherent model drug preference for the oily environment of the lipoidal region and the inherent model drug dislike for the hydrophilic corneocyte interior. Therefore, the oleic acid is observed to increase the hydrophobic model drug solubility in the lipid region, while decreasing the hydrophobic model drug penetration into the corneocyte region. The increased model drug concentrations in the lipoidal region of the SC, resulting from increased model drug partitioning, are localized to the intercellular region such that hydrophobic model drug di¡usion is con¢ned to lateral di¡usion. For the hydrophilic model drug, however, a di¡erent mechanism of transport enhancement was observed. The oleic acid-induced increases in hydrophilic model drug partitioning into the SC lipid multilamellar region drives the hydrophilic model drug from the lipid region into the hydrophilic corneocyte interior. Whereas circumventing transport into the corneocytes promoted hydrophobic model drug transport, transport enhancement for the hydrophilic model drug resulted in increased intracorneocyte di¡usion.
CONCLUSIONS
The application of DHTPM to delineate the oleic acid-induced changes in the permeant transdermal pathways has been introduced to elucidate the mechanisms of chemical enhancer action. Oleic acid was found to induce increases in the SRB intracorneocyte di¡usion and in the localization of the RBHE model drug di¡usion to the intercellular region.
Although the extent of lipid to corneocyte partitioning depends, in part, on the speci¢c physicochemical properties of the Figure 4 . Peak-width image analysis of the hydrophilic model drug (SRB) intensity spectrum. For the control case, the linear £uorescence intensity deconstruction regions are outlined by the white rectangles in the images of the SRB model drug spatial distribution, shown in (a), and of the corresponding skin auto£uorescence signal, shown in (c). The green and the red lines in (b) represent the skin auto£uorescence and the model drug intensity spectra, respectively. For the chemical enhancer (oleic acid) case, the white rectangles in (d) and (f) show the linear £uorescence intensity deconstruction regions for the images of the model drug spatial distribution and of the skin auto£uorescence, respectively. The green and the red lines shown in (e) depict the intensity spectra for the skin auto£uorescence and for the model drug, respectively. See the text for details.
hydrophobic and the hydrophilic model drugs, the mechanistic insight provided here poses the question of how localizing the chemically induced enhancement of transdermal permeant di¡u-sion to the intercellular region may further increase the skin permeabilities to hydrophilic permeants currently achieved with well-known, e¡ective chemical enhancer formulations. The dual function of the corneocytes in the scheme of chemically induced transdermal transport warrants further analyses. In particular, the precise role of intracorneocyte di¡usion in enhancing or hindering transport remains to be elucidated.
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